RECORD // Company

Onconetix, Inc.

Formerly: Blue Water Biotech, Inc.; Blue Water Vaccines Inc.

Built 2026-11-22T03:45:51Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001213900-26-120764

ItemValuePeriodFormFiledAccessionReport
Revenue$102,8843 months ended 2026-09-3010-Q2026-11-160001213900-26-1207642026-11-22 03:45 UTCReport an error
Net income (loss)$-31,627,9313 months ended 2026-09-3010-Q2026-11-160001213900-26-1207642026-11-22 03:45 UTCReport an error
Interest expense$3,2463 months ended 2026-09-3010-Q2026-11-160001213900-26-1207642026-11-22 03:45 UTCReport an error
Cash and cash equivalents$2,741,657at 2026-09-3010-Q2026-11-160001213900-26-1207642026-11-22 03:45 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001782107
Ticker
ONCO
CUSIP
68237Q401
Record ID
sx:sec:0001782107

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

27 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 03:45 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 03:45 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 03:45 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 03:45 UTCReport an error
Business address201 E. FIFTH STREET, SUITE 1900, CINCINNATI, OH, 452022026-11-16SEC EDGAR company profile2026-11-22 03:45 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 03:45 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$815,3712025-12-3110-K, XBRL Revenues2026-11-22 03:45 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-14,032,3422025-12-3110-K, XBRL NetIncomeLoss2026-11-22 03:45 UTCReport an error
Total assets (at 2025-12-31)$24,926,6382025-12-3110-K, XBRL Assets2026-11-22 03:45 UTCReport an error
Stockholders' equity (at 2025-12-31)$15,764,6272025-12-3110-K, XBRL StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest2026-11-22 03:45 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$5,220,6542025-12-3110-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents2026-11-22 03:45 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-9,678,3902025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 03:45 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2024-12-31)$28,4712024-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 03:45 UTCReport an error
Form D total offering amount (D filed 2025-10-07)$12,977,6702025-10-07D2026-11-22 03:45 UTCReport an error
Form D total amount sold (D filed 2025-10-07)$12,977,6702025-10-07D2026-11-22 03:45 UTCReport an error
Form D industry groupBiotechnology2025-10-07D2026-11-22 03:45 UTCReport an error
Form D revenue range$1 - $1,000,0002025-10-07D2026-11-22 03:45 UTCReport an error
Form D date of first sale2025-09-222025-10-07D2026-11-22 03:45 UTCReport an error
8-K Item 5.07, Submission of Matters to a (filed 2026-11-12)Vote of Security Holders. On November 10, 2026, Onconetix, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting were: (1) the election of Josh Epstein to serve as a Class II director on the Company’s Board of Directors (the “Board”) for a three-year term that expires at the 2029 Annual Meeting of Stockholders, or until his successor is elected and qualified (the “Director Election Proposal”); (2) the approval, in accordance with Nasdaq Listing Rule 5635, the issuance of up to 154,856,150 shares of the Company’s Common Stock, par value $0.00001 per share (“Common Stock”) subject to adjustment, upon conversion of…2026-11-12SEC EDGAR 8-K 0001213900-26-118266 (text as filed, excerpt)2026-11-22 03:45 UTCReport an error
8-K Item 5.03, Amendments to Articles of Incorporation (filed 2026-11-09)or Bylaws; Change in Fiscal Year. As previously disclosed in a Current Report on Form 8-K filed on October 26, 2026, on October 22, 2026, the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”) approved a one-for-ten (1:10) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock, par value $0.00001 per share (the “Common Stock”), pursuant to the authority granted by the Company’s stockholders at a special meeting held on April 30, 2026. On November 4, 2026, the Company filed a Certificate of Amendment (the “Amendment”) to its Amended and Restated Certificate of Incorporation, as amended (the “Charter”), with the Secretary of State…2026-11-09SEC EDGAR 8-K 0001213900-26-117223 (text as filed, excerpt)2026-11-22 03:45 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive (filed 2026-11-06)Agreement. First Amendment to Share Exchange Agreement As previously disclosed, on February 11, 2026, Onconetix, Inc., a Delaware corporation (“Onconetix” or “Buyer”), entered into a Share Exchange Agreement (the “Share Exchange Agreement”), by and among (i) Onconetix, (ii) Realbotix Corp., a company existing under the laws of the Province of Ontario (“Parent”), (iii) Simulacra Corporation, a Delaware corporation and a wholly-owned subsidiary of Parent (the “Seller”), and (iv) Realbotix, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Seller (“Realbotix”). Unless otherwise defined herein, the capitalized terms used below are defined in the Share Exchange…2026-11-06SEC EDGAR 8-K 0001213900-26-116512 (text as filed, excerpt)2026-11-22 03:45 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-26)As previously reported on a Current Report on Form 8-K filed on May 4, 2026, Onconetix, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) on April 30, 2026. At the Special Meeting, the Company’s stockholders approved the proposal to grant discretionary authority to the Company’s Board of Directors (the “Board”) to amend the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect one or more reverse stock splits of the Company’s issued and outstanding common stock, par value $0.00001 per share (the “Common Stock”), at ratios ranging from one-for-two (1:2) to one-for-ten (1:10), at any time prior to the one-year…2026-10-26SEC EDGAR 8-K 0001213900-26-112527 (text as filed, excerpt)2026-11-22 03:45 UTCReport an error
Largest institutional holder #1 (13F as filed): XTX Topco Ltd$15,3092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:45 UTCReport an error
Largest institutional holder #2 (13F as filed): SBI Securities Co., Ltd.$2852026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:45 UTCReport an error
Largest institutional holder #3 (13F as filed): Tower Research Capital LLC (TRC)$1642026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:45 UTCReport an error
Largest institutional holder #4 (13F as filed): HOLLENCREST CAPITAL MANAGEMENT$1132026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:45 UTCReport an error
Largest institutional holder #5 (13F as filed): HRT FINANCIAL LP$582026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:45 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.